ORYZON Reports Financial Results and Corporate Update for the Fourth Quarter and Year Ended December 31, 2016

BARCELONA, SPAIN and CAMBRIDGE MA.

Oryzon Genomics (Madrid Stock Exchange: ORY) (ISIN Code: ES0167733015), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the fourth quarter of 2016 and provided an update on the Company's recent developments.

Click here to see the full Press Release